Opdivo-Yervoy Combo Showing Efficacy in Aggressive Prostate Cancer Patients with Select Mutations

Opdivo-Yervoy Combo Showing Efficacy in Aggressive Prostate Cancer Patients with Select Mutations
A combination of two approved immunotherapies — Opdivo (nivolumab) and Yervoy (ipilimumab) — appears to delay cancer progression and lengthen survival in a subset of patients with an aggressive form of castration-resistant prostate cancer, results from an ongoing pilot trial led by Johns Hopkins School of Medicine show. The study, “Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer,” was published in the journal Oncotarget. It targeted patients with AR-V7-positive prostate cancer — tumors that produce a variant of the androgen receptor that is resistant to current hormone therapies. These patients generally have a median overall survival of seven to nine months. This type of prostate cancer was first discovered by a Johns Hopkins
Subscribe or to access all post and page content.